GSK and Ionis present pivotal data showing 19% functional cure for chronic hepatitis B
GSK (NYSE:GSK) and partner Ionis Pharmaceuticals (NASDAQ:IONS) announced positive data from two pivotal Phase 3 trials evaluating bepirovirsen, an investigational antisense oligonucleotide designed to treat chronic hepatitis B.





-640x359.webp&w=3840&q=75)




